Stryker Corporation (NYSE:SYK) Shares Acquired by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. increased its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 4.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,951 shares of the medical technology company's stock after buying an additional 852 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Stryker were worth $7,055,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Stryker by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after buying an additional 252,188 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Stryker by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock worth $4,000,056,000 after purchasing an additional 54,693 shares during the period. FMR LLC raised its holdings in Stryker by 10.0% in the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after purchasing an additional 727,850 shares during the period. Geode Capital Management LLC raised its holdings in shares of Stryker by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after acquiring an additional 168,436 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Stryker during the fourth quarter valued at approximately $1,710,744,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Down 0.5%

NYSE SYK traded down $1.99 during trading on Wednesday, reaching $387.52. 117,599 shares of the company's stock were exchanged, compared to its average volume of 1,345,705. The stock has a market cap of $147.91 billion, a P/E ratio of 52.46, a price-to-earnings-growth ratio of 2.96 and a beta of 0.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. The company has a 50 day moving average price of $383.81 and a two-hundred day moving average price of $376.67. Stryker Corporation has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The business had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same quarter in the previous year, the firm earned $2.50 earnings per share. The business's revenue was up 11.9% compared to the same quarter last year. On average, equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SYK. Citigroup reissued a "buy" rating and set a $455.00 target price (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Roth Mkm upped their price target on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Needham & Company LLC restated a "buy" rating and issued a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. JMP Securities restated a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Finally, Truist Financial increased their price objective on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $428.55.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.